Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities

36Citations
Citations of this article
119Readers
Mendeley users who have this article in their library.

Abstract

The molecular pathogenesis of hematological diseases is often driven by genetic and epigenetic alterations. Next-generation sequencing has considerably increased our genomic knowledge of these disorders becoming ever more widespread in clinical practice. In 2012 Oxford Nanopore Technologies (ONT) released the MinION, the first long-read nanopore-based sequencer, overcoming the main limits of short-reads sequences generation. In the last years, several nanopore sequencing approaches have been performed in various “-omic” sciences; this review focuses on the challenge to introduce ONT devices in the hematological field, showing advantages, disadvantages and future perspectives of this technology in the precision medicine era.

Cite

CITATION STYLE

APA

Minervini, C. F., Cumbo, C., Orsini, P., Anelli, L., Zagaria, A., Specchia, G., & Albano, F. (2020, February 19). Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities. Frontiers in Genetics. Frontiers Media S.A. https://doi.org/10.3389/fgene.2020.00076

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free